Loading…
Evaluation and comparison of eighteen SARS-CoV-2 antibody assays from seven different companies to assess its diagnostic role in SARS-CoV-2 infections
The diagnostic performance of reverse transcriptase polymerase chain reaction (RT-PCR) decreases during the late acute stage of the corona virus disease (COVID-19) infection; hence, serological assays can be used for disease diagnosis in patients non-protected through vaccinations at this stage. The...
Saved in:
Published in: | The New microbiologica 2022-12, Vol.45 (4), p.344-352 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | 352 |
container_issue | 4 |
container_start_page | 344 |
container_title | The New microbiologica |
container_volume | 45 |
creator | Yurttutan Uyar, Neval Ahmet, Arda Serdar, Muhittin Kocagöz, Sesin Kilercik, Meltem Serteser, Mustafa |
description | The diagnostic performance of reverse transcriptase polymerase chain reaction (RT-PCR) decreases during the late acute stage of the corona virus disease (COVID-19) infection; hence, serological assays can be used for disease diagnosis in patients non-protected through vaccinations at this stage. The objective of this study was to assess the diagnostic accuracy of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody tests in current/past infections, determine proper testing time, and check the accuracy of cutoff values. In this study, 18 Ig (immunoglobulin) G, IgM, IgA, and total antibody serological assays were performed using 839 samples. Positive sera (n=132) were collected during the first 5 months after the patients were symptomatic and tested positive for the SARS-CoV-2 RT-PCR test; they were grouped as 0-10, 10-15, >15 days according to the symptom onset. Negative sera (N=707) were obtained from patients with lupus before the pandemic. The performance of IgG and total antibody assays was better than those of IgA, IgM, and IgA-IgM for all post-symptom groups except for 0-10 days, which showed lower Ig assay sensitivity. During 10-15 and >15 days, >70% sensitivity to IgA, IgM, IgM-IgA assays and lower sensitivity were noted, respectively. The sensitivities of IgG and total antibody assays for group C were slightly lower than that of group B. There were no significant differences, but there were higher correlations between the methods or antigenic structures. Receiving operating characteristics (ROC) analysis revealed better cutoff values. For the diagnosis of late acute/past SARS-CoV-2 infection, serological tests can be performed on unvaccinated patients showing symptoms for ≥10 days. SARS-CoV-2 IgG and total antibodies were better diagnostic markers than IgM, IgA, and IgM+IgA, which were restricted to group B. |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_2756121472</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2756216779</sourcerecordid><originalsourceid>FETCH-LOGICAL-p239t-1cb2b8aad05b670246f10c1810677860d6c7ba12a1215eb95ac26a45234a1cc33</originalsourceid><addsrcrecordid>eNpd0N1KwzAUB_BeKG7MvYIEvPGmkI82bS_HmB8wEJx6W9L0dGa0Se1JB3sRn9fMzQsNB0Lgd_7nkItoyhhnccZEPonmiDsajkwZL_hVNBEyFbmgdBp9rfaqHZU3zhJla6Jd16vBYHi6hoDZfngASzaLl028dO8xD8qbytUHohDVAUkzuI4g7IOqTdPAANafYqwBJN4dISAS4zEItbUOvdFkcC0Q8yfa2Ab0cRW8ji4b1SLMz_csertfvS4f4_Xzw9NysY57LgofM13xKleqpmklM8oT2TCqWc6ozLJc0lrqrFKMh2IpVEWqNJcqSblIFNNaiFl0d8rtB_c5AvqyM6ihbZUFN2LJs1SG3iTjgd7-ozs3DjZs96M4CyOLoG7Oaqw6qMt-MJ0aDuXvj4tvnpx8Yg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2756216779</pqid></control><display><type>article</type><title>Evaluation and comparison of eighteen SARS-CoV-2 antibody assays from seven different companies to assess its diagnostic role in SARS-CoV-2 infections</title><source>EZB Electronic Journals Library</source><creator>Yurttutan Uyar, Neval ; Ahmet, Arda ; Serdar, Muhittin ; Kocagöz, Sesin ; Kilercik, Meltem ; Serteser, Mustafa</creator><creatorcontrib>Yurttutan Uyar, Neval ; Ahmet, Arda ; Serdar, Muhittin ; Kocagöz, Sesin ; Kilercik, Meltem ; Serteser, Mustafa</creatorcontrib><description>The diagnostic performance of reverse transcriptase polymerase chain reaction (RT-PCR) decreases during the late acute stage of the corona virus disease (COVID-19) infection; hence, serological assays can be used for disease diagnosis in patients non-protected through vaccinations at this stage. The objective of this study was to assess the diagnostic accuracy of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody tests in current/past infections, determine proper testing time, and check the accuracy of cutoff values. In this study, 18 Ig (immunoglobulin) G, IgM, IgA, and total antibody serological assays were performed using 839 samples. Positive sera (n=132) were collected during the first 5 months after the patients were symptomatic and tested positive for the SARS-CoV-2 RT-PCR test; they were grouped as 0-10, 10-15, >15 days according to the symptom onset. Negative sera (N=707) were obtained from patients with lupus before the pandemic. The performance of IgG and total antibody assays was better than those of IgA, IgM, and IgA-IgM for all post-symptom groups except for 0-10 days, which showed lower Ig assay sensitivity. During 10-15 and >15 days, >70% sensitivity to IgA, IgM, IgM-IgA assays and lower sensitivity were noted, respectively. The sensitivities of IgG and total antibody assays for group C were slightly lower than that of group B. There were no significant differences, but there were higher correlations between the methods or antigenic structures. Receiving operating characteristics (ROC) analysis revealed better cutoff values. For the diagnosis of late acute/past SARS-CoV-2 infection, serological tests can be performed on unvaccinated patients showing symptoms for ≥10 days. SARS-CoV-2 IgG and total antibodies were better diagnostic markers than IgM, IgA, and IgM+IgA, which were restricted to group B.</description><identifier>ISSN: 1121-7138</identifier><identifier>PMID: 36538300</identifier><language>eng</language><publisher>Italy: Edizioni Medico Scientifiche</publisher><subject>Antibodies ; Antibodies, Viral ; Antigens ; Assaying ; Autoimmune diseases ; Coronaviruses ; COVID-19 ; COVID-19 - diagnosis ; Diagnosis ; Diagnostic systems ; Humans ; Immunoglobulin A ; Immunoglobulin G ; Immunoglobulin M ; Infections ; Pandemics ; Polymerase chain reaction ; Respiratory diseases ; RNA-directed DNA polymerase ; SARS-CoV-2 ; Sensitivity ; Sensitivity and Specificity ; Serological tests ; Serology ; Severe acute respiratory syndrome coronavirus 2 ; Signs and symptoms ; Viral diseases ; Viruses</subject><ispartof>The New microbiologica, 2022-12, Vol.45 (4), p.344-352</ispartof><rights>Copyright Edizioni Medico Scientifiche Oct 2022</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36538300$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yurttutan Uyar, Neval</creatorcontrib><creatorcontrib>Ahmet, Arda</creatorcontrib><creatorcontrib>Serdar, Muhittin</creatorcontrib><creatorcontrib>Kocagöz, Sesin</creatorcontrib><creatorcontrib>Kilercik, Meltem</creatorcontrib><creatorcontrib>Serteser, Mustafa</creatorcontrib><title>Evaluation and comparison of eighteen SARS-CoV-2 antibody assays from seven different companies to assess its diagnostic role in SARS-CoV-2 infections</title><title>The New microbiologica</title><addtitle>New Microbiol</addtitle><description>The diagnostic performance of reverse transcriptase polymerase chain reaction (RT-PCR) decreases during the late acute stage of the corona virus disease (COVID-19) infection; hence, serological assays can be used for disease diagnosis in patients non-protected through vaccinations at this stage. The objective of this study was to assess the diagnostic accuracy of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody tests in current/past infections, determine proper testing time, and check the accuracy of cutoff values. In this study, 18 Ig (immunoglobulin) G, IgM, IgA, and total antibody serological assays were performed using 839 samples. Positive sera (n=132) were collected during the first 5 months after the patients were symptomatic and tested positive for the SARS-CoV-2 RT-PCR test; they were grouped as 0-10, 10-15, >15 days according to the symptom onset. Negative sera (N=707) were obtained from patients with lupus before the pandemic. The performance of IgG and total antibody assays was better than those of IgA, IgM, and IgA-IgM for all post-symptom groups except for 0-10 days, which showed lower Ig assay sensitivity. During 10-15 and >15 days, >70% sensitivity to IgA, IgM, IgM-IgA assays and lower sensitivity were noted, respectively. The sensitivities of IgG and total antibody assays for group C were slightly lower than that of group B. There were no significant differences, but there were higher correlations between the methods or antigenic structures. Receiving operating characteristics (ROC) analysis revealed better cutoff values. For the diagnosis of late acute/past SARS-CoV-2 infection, serological tests can be performed on unvaccinated patients showing symptoms for ≥10 days. SARS-CoV-2 IgG and total antibodies were better diagnostic markers than IgM, IgA, and IgM+IgA, which were restricted to group B.</description><subject>Antibodies</subject><subject>Antibodies, Viral</subject><subject>Antigens</subject><subject>Assaying</subject><subject>Autoimmune diseases</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 - diagnosis</subject><subject>Diagnosis</subject><subject>Diagnostic systems</subject><subject>Humans</subject><subject>Immunoglobulin A</subject><subject>Immunoglobulin G</subject><subject>Immunoglobulin M</subject><subject>Infections</subject><subject>Pandemics</subject><subject>Polymerase chain reaction</subject><subject>Respiratory diseases</subject><subject>RNA-directed DNA polymerase</subject><subject>SARS-CoV-2</subject><subject>Sensitivity</subject><subject>Sensitivity and Specificity</subject><subject>Serological tests</subject><subject>Serology</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Signs and symptoms</subject><subject>Viral diseases</subject><subject>Viruses</subject><issn>1121-7138</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNpd0N1KwzAUB_BeKG7MvYIEvPGmkI82bS_HmB8wEJx6W9L0dGa0Se1JB3sRn9fMzQsNB0Lgd_7nkItoyhhnccZEPonmiDsajkwZL_hVNBEyFbmgdBp9rfaqHZU3zhJla6Jd16vBYHi6hoDZfngASzaLl028dO8xD8qbytUHohDVAUkzuI4g7IOqTdPAANafYqwBJN4dISAS4zEItbUOvdFkcC0Q8yfa2Ab0cRW8ji4b1SLMz_csertfvS4f4_Xzw9NysY57LgofM13xKleqpmklM8oT2TCqWc6ozLJc0lrqrFKMh2IpVEWqNJcqSblIFNNaiFl0d8rtB_c5AvqyM6ihbZUFN2LJs1SG3iTjgd7-ozs3DjZs96M4CyOLoG7Oaqw6qMt-MJ0aDuXvj4tvnpx8Yg</recordid><startdate>202212</startdate><enddate>202212</enddate><creator>Yurttutan Uyar, Neval</creator><creator>Ahmet, Arda</creator><creator>Serdar, Muhittin</creator><creator>Kocagöz, Sesin</creator><creator>Kilercik, Meltem</creator><creator>Serteser, Mustafa</creator><general>Edizioni Medico Scientifiche</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7QL</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>M7N</scope><scope>7X8</scope></search><sort><creationdate>202212</creationdate><title>Evaluation and comparison of eighteen SARS-CoV-2 antibody assays from seven different companies to assess its diagnostic role in SARS-CoV-2 infections</title><author>Yurttutan Uyar, Neval ; Ahmet, Arda ; Serdar, Muhittin ; Kocagöz, Sesin ; Kilercik, Meltem ; Serteser, Mustafa</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p239t-1cb2b8aad05b670246f10c1810677860d6c7ba12a1215eb95ac26a45234a1cc33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antibodies</topic><topic>Antibodies, Viral</topic><topic>Antigens</topic><topic>Assaying</topic><topic>Autoimmune diseases</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 - diagnosis</topic><topic>Diagnosis</topic><topic>Diagnostic systems</topic><topic>Humans</topic><topic>Immunoglobulin A</topic><topic>Immunoglobulin G</topic><topic>Immunoglobulin M</topic><topic>Infections</topic><topic>Pandemics</topic><topic>Polymerase chain reaction</topic><topic>Respiratory diseases</topic><topic>RNA-directed DNA polymerase</topic><topic>SARS-CoV-2</topic><topic>Sensitivity</topic><topic>Sensitivity and Specificity</topic><topic>Serological tests</topic><topic>Serology</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Signs and symptoms</topic><topic>Viral diseases</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yurttutan Uyar, Neval</creatorcontrib><creatorcontrib>Ahmet, Arda</creatorcontrib><creatorcontrib>Serdar, Muhittin</creatorcontrib><creatorcontrib>Kocagöz, Sesin</creatorcontrib><creatorcontrib>Kilercik, Meltem</creatorcontrib><creatorcontrib>Serteser, Mustafa</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><jtitle>The New microbiologica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yurttutan Uyar, Neval</au><au>Ahmet, Arda</au><au>Serdar, Muhittin</au><au>Kocagöz, Sesin</au><au>Kilercik, Meltem</au><au>Serteser, Mustafa</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation and comparison of eighteen SARS-CoV-2 antibody assays from seven different companies to assess its diagnostic role in SARS-CoV-2 infections</atitle><jtitle>The New microbiologica</jtitle><addtitle>New Microbiol</addtitle><date>2022-12</date><risdate>2022</risdate><volume>45</volume><issue>4</issue><spage>344</spage><epage>352</epage><pages>344-352</pages><issn>1121-7138</issn><abstract>The diagnostic performance of reverse transcriptase polymerase chain reaction (RT-PCR) decreases during the late acute stage of the corona virus disease (COVID-19) infection; hence, serological assays can be used for disease diagnosis in patients non-protected through vaccinations at this stage. The objective of this study was to assess the diagnostic accuracy of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody tests in current/past infections, determine proper testing time, and check the accuracy of cutoff values. In this study, 18 Ig (immunoglobulin) G, IgM, IgA, and total antibody serological assays were performed using 839 samples. Positive sera (n=132) were collected during the first 5 months after the patients were symptomatic and tested positive for the SARS-CoV-2 RT-PCR test; they were grouped as 0-10, 10-15, >15 days according to the symptom onset. Negative sera (N=707) were obtained from patients with lupus before the pandemic. The performance of IgG and total antibody assays was better than those of IgA, IgM, and IgA-IgM for all post-symptom groups except for 0-10 days, which showed lower Ig assay sensitivity. During 10-15 and >15 days, >70% sensitivity to IgA, IgM, IgM-IgA assays and lower sensitivity were noted, respectively. The sensitivities of IgG and total antibody assays for group C were slightly lower than that of group B. There were no significant differences, but there were higher correlations between the methods or antigenic structures. Receiving operating characteristics (ROC) analysis revealed better cutoff values. For the diagnosis of late acute/past SARS-CoV-2 infection, serological tests can be performed on unvaccinated patients showing symptoms for ≥10 days. SARS-CoV-2 IgG and total antibodies were better diagnostic markers than IgM, IgA, and IgM+IgA, which were restricted to group B.</abstract><cop>Italy</cop><pub>Edizioni Medico Scientifiche</pub><pmid>36538300</pmid><tpages>9</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1121-7138 |
ispartof | The New microbiologica, 2022-12, Vol.45 (4), p.344-352 |
issn | 1121-7138 |
language | eng |
recordid | cdi_proquest_miscellaneous_2756121472 |
source | EZB Electronic Journals Library |
subjects | Antibodies Antibodies, Viral Antigens Assaying Autoimmune diseases Coronaviruses COVID-19 COVID-19 - diagnosis Diagnosis Diagnostic systems Humans Immunoglobulin A Immunoglobulin G Immunoglobulin M Infections Pandemics Polymerase chain reaction Respiratory diseases RNA-directed DNA polymerase SARS-CoV-2 Sensitivity Sensitivity and Specificity Serological tests Serology Severe acute respiratory syndrome coronavirus 2 Signs and symptoms Viral diseases Viruses |
title | Evaluation and comparison of eighteen SARS-CoV-2 antibody assays from seven different companies to assess its diagnostic role in SARS-CoV-2 infections |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T16%3A35%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20and%20comparison%20of%20eighteen%20SARS-CoV-2%20antibody%20assays%20from%20seven%20different%20companies%20to%20assess%20its%20diagnostic%20role%20in%20SARS-CoV-2%20infections&rft.jtitle=The%20New%20microbiologica&rft.au=Yurttutan%20Uyar,%20Neval&rft.date=2022-12&rft.volume=45&rft.issue=4&rft.spage=344&rft.epage=352&rft.pages=344-352&rft.issn=1121-7138&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E2756216779%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p239t-1cb2b8aad05b670246f10c1810677860d6c7ba12a1215eb95ac26a45234a1cc33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2756216779&rft_id=info:pmid/36538300&rfr_iscdi=true |